Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

被引：0
|
作者：
Jithma P. Abeykoon
Saurabh Zanwar
Angela Dispenzieri
Morie A. Gertz
Nelson Leung
Taxiarchis Kourelis
Wilson Gonsalves
Eli Muchtar
David Dingli
Martha Q. Lacy
Suzanne R. Hayman
Francis Buadi
Rahma Warsame
Robert A. Kyle
Vincent Rajkumar
Shaji Kumar
Prashant Kapoor
机构：
[1] Mayo Clinic,Department of Internal Medicine
[2] Division of Hematology,undefined
[3] Mayo Clinic,undefined
[4] Division of Nephrology,undefined
[5] Mayo Clinic,undefined
来源：
Leukemia | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：531 / 536
页数：5
相关论文
共 50 条
  • [1] Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
    Abeykoon, Jithma P.
    Zanwar, Saurabh
    Dispenzieri, Angela
    Gertz, Morie A.
    Leung, Nelson
    Kourelis, Taxiarchis
    Gonsalves, Wilson
    Muchtar, Eli
    Dingli, David
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Buadi, Francis
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, Vincent
    Kumar, Shaji
    Kapoor, Prashant
    LEUKEMIA, 2019, 33 (02) : 531 - 536
  • [2] Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
    Lakshman, Arjun
    Abeykoon, Jithma P.
    Kumar, Shaji
    Rajkumar, S. Vincent
    Kourelis, Taxiarchis
    Buadi, Francis
    Dingli, David
    Lacy, Martha
    Gonsalves, Wilson I.
    Dispenzieri, Angela
    Kyle, Robert A.
    Lin, Yi
    Go, Ronald S.
    Warsame, Rahma M.
    Hayman, Suzanne R.
    Russell, Stephen
    Leung, Nelson
    Gertz, Morie A.
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Fotiou, Despina
    Roussou, Maria
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Migkou, Magdalini
    Papaiakovou, Evangelos Eleutherakis
    Kanellias, Nikolaos
    Papanikolaou, Asimina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios-Athanasios
    Kastritis, Efstathios
    BLOOD, 2022, 140 : 4275 - 4276
  • [4] Daratumumab-based therapies in patients with AL amyloidosis.
    Abeykoon, Jithma P.
    Zanwar, Saurabh
    Kumar, Shaji
    Dispenzieri, Angela
    Rajkumar, S. Vincent
    Lacy, Martha
    Dingli, David
    Leung, Nelson
    Muchtar, Eli
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Buadi, Francis
    Kyle, Robert A.
    Gertz, Morie A.
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy
    Theodorakakou, Foteini
    Fotiou, Despina
    Spiliopoulou, Vasiliki
    Roussou, Maria
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Papanikolaou, Asimina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (03) : 411 - 415
  • [6] Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review
    Ehsan, Hamid
    Rafae, Abdul
    Masood, Adeel
    Wahab, Ahsan
    Sana, Muhammad Khawar
    Ansar, Iqraa
    Neupane, Karun
    Umar, Arooj
    Ehsan, Amrat
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : E285 - E292
  • [7] Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
    Kaufman, Gregory P.
    Schrier, Stanley L.
    Lafayette, Richard A.
    Arai, Sally
    Witteles, Ronald M.
    Liedtke, Michaela
    BLOOD, 2017, 130 (07) : 900 - 902
  • [8] Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience
    Dima, Danai
    Hu, Xiao
    Dower, Joshua
    Comenzo, Raymond L.
    Varga, Cindy
    BLOOD, 2020, 136
  • [9] DARATUMUMAB IN HEAVILY PRETREATED, TRANSPLANT INELIGIBLE, AL AMYLOIDOSIS PATIENTS: A SINGLE CENTRE EXPERIENCE
    Riva, M.
    Scapinello, G.
    Ammirati, L.
    Lessi, F.
    Branca, A.
    Zambello, R.
    Piazza, F.
    Semenzato, G.
    Berno, T.
    HAEMATOLOGICA, 2019, 104 : 64 - 65
  • [10] Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review
    Rahman, Muhammad Aadil
    Khan, Ali Younas
    Ijaz, Awais
    Tariq, Muhammad Junaid
    Usman, Muhammad
    Khalil, Muhammad Jahanzeb
    Fraz, Muhammad Asad
    Jamil, Faiza
    Rafae, Abdul
    Malik, Mustafa Nadeem
    Selene, Insija Ilyas
    Jose, Jemin Aby
    Safdar, Ahmad
    McBride, Ali
    Anwer, Faiz
    BLOOD, 2018, 132
12345